Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical ...
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results ...
Atossa Genetics (NasdaqCM: ATOS) is a medical diagnostics company focused on the prevention of breast cancer through the development and commercialization of diagnostic tests that can detect ...
Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...
What To Know: The FDA granted one of the biopharmaceutical company’s potential treatments, (Z)-Endoxifen, a rare pediatric disease designation for the treatment of Duchenne Muscular Dystrophy. The ...
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
The MarketWatch News Department was not involved in the creation of this content. SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a ...
Atossa Genetics, a Seattle company that’s developing and marketing diagnostic tests for precursors to breast cancer, filed paperwork Tuesday to raise about $6 million in an initial public stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results